Pharmacological profile of omalizumab;Perfil farmacológico del omalizumab

Archivos de Bronconeumologia

Volumn 42, Issue SUPPL.1, 2006, Pages 26-31

  Cabrera Navarro, Pedro ^a   Gallego, José Carlos Rodríguez ^a  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

Anti IgE; Anti immunoglobulin E. Xolair ; Omalizumab

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; CETUXIMAB; DACLIZUMAB; EFALIZUMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN E; INFLIXIMAB; MONOCLONAL ANTIBODY; OKT 3; OMALIZUMAB; PALIVIZUMAB; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB;

AIRWAY OBSTRUCTION; ALLERGIC DISEASE; ASTHMA; BRONCHUS HYPERREACTIVITY; CYTOLOGY; DRUG MECHANISM; HUMAN; INFLAMMATION; MOLECULAR BIOLOGY; PATHOGENESIS; PHENOTYPE; REVIEW; RHINITIS;

EID: 34547689019     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1157/13097254     Document Type: Article

References (48)

1. Liossis SN, Tsokos GC. Monoclonal antibodies and fusion proteins in medicine. J Allergy Clin Immunol. 2005;116721-9.
2. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med. 2006;354:697-708.
3. Nelson PN, Reynolds GM, Waldron EE, et al. Monoclonal antibodies. J Clin Pathol Mol Pathol. 2000;53:111-7.
4. Presta LG. Selection, design, and engineering of therapeutic antibodies. J Allergy Clin Immunol. 2005;116:731-6.
5. Burrows B, Martinez FD, Halonen A, et al. Association of asthma with serum IgE levels and skin test reactivity to allergens. N Engl J Med. 1989;320:271-7.
6. Sears MR, Burrows B, Flannery EM, et al. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med. 1991;325:1067-71.
7. Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 2002;110:685-92.
8. Torres R, Picado C, De Mora F. Descubriendo el asma de origen alérgico a través del ratón. Un repaso a la patogenia de los modelos de asma alérgica en el ratón y su similitud con el asma alérgica humana. Arch Bronconeumol. 2005;41:141-52.
9. Saini SS, MacGlashan DW Jr, Sterbinsky SA, et al. Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol. 1999;162:5624-30.
10. Oettgen HC, Geha RS. IgE in asthma and atopy: cellular and molecular connections. J Clin Invest. 1999;104:829-35.
11. Ross JS, Schenkein DP, Pietrusko R, et al. Targeted therapies for cancer 2004. Am J Clin Pathol. 2004;122:598-609.
12. Beeh KM, Ksoll M, Buhl R. Elevation of total serum immunoglobulin E is associated with asthma in nonallergic individuals. Eur Respir J. 2000;16:609-14.
13. Leckie MJ, Ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet. 2000;356:2144-8.
14. Flood-Page PT, Menzies-Gow AN, Kay AB, et al. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167:199-204.
15. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest. 2003;112:1029-36.
16. Barnes PJ. Cytokine-directed therapies for asthma. J Allergy Clin Immunol. 2001;108:S72-6.
17. Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol. 1993;151:2623-32.
18. Breedveld FC. Therapeutic monoclonal antibodies. Lancet. 2000;355:735-40.
19. Easthope S, Jarvis B. Omalizumab. Drugs. 2001;61:253-60.
20. Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol. 2000;18:157-62.
21. Thomas D, Saban R, Jardieu P. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol. 1995;107:308-12.
22. Milgrom H, Fick RB Jr, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med. 1999;341:1966-73.
23. Malveaux FJ, Conroy MC, Adkinson NF Jr, et al. IgE receptors on human basophils. Relationship to serum IgE concentration. J Clin Invest. 1978;62:176-81.
24. Rajakulasingam K, Till S, Ying S, et al. Increased expression of high affinity IgE (Fc epsilon RI) receptor-alpha chain mRNA and protein-bearing eosinophils in human allergen-induced atopic asthma. Am J Respir Crit Care Med. 1998;158:233-40.
25. MacGlashan DW Jr, Bochner BS, Adelman DC, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997;158:1438-45.
26. Djukanovic R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody Omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170:583-93.
27. Schulman ES. Development of a monoclonal anti-immunoglobulin E antibody (Omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med. 2001;164:S6-11.
28. Casale TB, Condemi J, La Force C, et al; Omalizumab Seasonal Allergic Rhinitis Trail Group. Effect of Omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA. 2001;286:2956-67.
29. Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2000;106:253-9.
30. Plewako H, Arvidsson M, Petruson K, et al. The effect of Omalizumab on nasal allergic inflammation. J Allergy Clin Immunol. 2002;110:68-71.
31. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with Omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59:709-17.
32. Hanf G, Noga O, O'Connor A, et al. Omalizumab inhibits allergen challenge-induced nasal response. Eur Respir J. 2004;23:414-8.
33. Chervinsky P, Casale T, Townley R, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2003;91:160-7.
34. Boulet LP, Chapman KR, Cote J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med. 1997;155:1835-40.
35. Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med. 1997;155:1828-34.
36. Soler M, Matz J, Townley R, et al. The anti-IgE antibody Omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18:254-61.
37. Lemanske RF Jr, Nayak A, McAlary M, et al. Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics. 2002;110:e55.
38. Holgate S, Bousquet J, Wenzel S, et al. Efficacy of Omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin. 2001;17:233-40.
39. Corren J, Casale T, Deniz Y, et al. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol. 2003;111:87-90.
40. Bousquet J, Wenzel S, Holgate S, et al. Predicting response to Omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest. 2004;125:1378-86.
41. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with Omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005;60:302-8.
42. Fahy JV, Cockcroft DW, Boulet LP, et al. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med. 1999;160:1023-7.
43. Berger W, Gupta N, McAlary M, et al. Evaluation of long-term safety of the anti-IgE antibody, Omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol. 2003;91:182-8.
44. Fox JA, Hotaling TE, Struble C, et al. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomologous monkeys. J Pharmacol Exp Ther. 1996;279:1000-8.
45. Liu J, Lester P, Builder S, et al. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry. 1995;34:10474-82.
46. Hagan P, Blumenthal UJ, Dunn D, et al. Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium. Nature. 1991;349:243-5.
47. Amiri P, Haak-Frendscho M, Robbins K, et al. Anti-immunoglobulin E treatment decreases worm burden and egg production in Schistosoma mansoni-infected normal and interferon gamma knockout mice. J Exp Med. 1994;180:43-51.
48. Cooper PJ, Lima F, Sarinho EC, Ayre G, Martin C, Fox H, et al. Safety of anti-IgE therapy with omalizumab in allergic patients at risk of geohelminth infection. Abstract AAAAI 62nd Annual Meeting. J Allergy Clin Immunol. 2006;117 (Suppl): S9.